Simultaneous succinylacetone-nitisinone measurement in tyrosinemia type I patients and evaluation of nitisinone therapeutic range

Author:

Öktem Rıdvan Murat1,İnci Aslı1,Biberoğlu Gürsel1,Okur İlyas1,Ezgü Fatih Süheyl1,Tümer Leyla1

Affiliation:

1. Gazi University

Abstract

Abstract Introduction: In tyrosinemia type I (HT1) accumulation of succinylacetone causes severe hepatic and renal dysfunction and hepatocellular carcinoma, and the only drug used in the treatment is nitisinone (NTBC). While succinylacetone measurement from dried blood spots (DBS) is used in the diagnosis of patients, simultaneous measurements of succinylacetone and NTBC are preferred in the treatment follow-up. The aim of this study was to evaluate the results of simultaneous LC-MS/MS analysis of succinylacetone and NTBC in HT1 patients. We also evaluated the plasma/DBS ratio and the upper therapeutic range for NTBC. Materials and method: Plasma and DBS samples from HT1 patients were used for succinylacetone and NTBC analyses and LC-MS/MS was used for simultaneous measurements of both of them. Results: The plasma/DBS ratio for NTBC was 1.92. The succinylacetone level, which was determined as the treatment goal, was suppressed (< 1 nmol/L) with the use of NTBC in 95.6% (109/114) of the cases. However, NTBC level was found above the therapeutic upper limit in 64.7% of these cases. Conclusion: The suppression rate of succinylacetone, which is one of the treatment targets for HT1, is high with 95.6%. However, the recommended therapeutic upper limit for NTBC was exceeded in 64.7% of the patients. It is also important to calculate the plasma/DBS NTBC ratio in laboratories analysing NTBC from DBS and to evaluate the therapeutic range targets according to this ratio. Evaluation of an individualized dose with a review of the therapeutic target may be considered in longitudinal studies examining clinical outcomes.

Publisher

Research Square Platform LLC

Reference23 articles.

1. Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations;Chinsky JM;Genet Med.,2017

2. Inter-laboratory analytical improvement of succinylacetone and nitisinone quantification from dried blood spot samples;Laeremans H;JIMD Rep. 2020 Apr

3. Recommendations for the management of tyrosinaemia type 1;Laet C;Orphanet J Rare Dis,2013

4. On the enzymic defects in hereditary tyrosinemia;Lindblad B;Proc Natl Acad Sci U S A,1977

5. Newborn screening for hepatorenal tyrosinemia: Tandem mass spectrometric quantification of succinylacetone;Sander J;Clin Chem,2006

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3